메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

산야에서 제8회 하이난 국제 건강산업 박람회 개막

[ 메디채널 김갑성 기자 ] 하이커우, 중국 2025년 12월 22일 -- 하이난 국제 미디어 센터 보도자료: 2025년 12월 20일 산야에서 제8회 하이난 국제 건강산업 박람회(Hainan International Health Industry)가 개최되었다. 하이난 자유무역항(Free Trade Port, FTP)에 독립적인 특별 통관 제도가 공식적으로 시행되는 중요한 시기와 맞물려 열린 박람회는 하이난이 건강 산업 발전상을 알리는 무대이자 건강 산업의 미래를 가늠할 수 있는 일종의 전망대 구실을 한다. 1만 2천 제곱미터 면적에서 나흘간 진행되는 올해의 박람회에는 253개의 국내외 기업이 참여하여 혁신적인 의약품, 의료 기기, 스마트 헬스케어, 재활 및 노인 요양, 전통 중의학, 고성능 건강 관리 제품을 출품했다. 세계 각국의 최첨단 기술, 제품, 서비스 방식을 전시하는 특별 국제 전시 구역(International Exhibition Area)도 별도로 마련되었다. 인공지능(AI) 보조 진단 시스템, 원격 의료 플랫폼, 최소 침습 수술 장비가 행사장을 방문한 건강 산업 전문가들의 큰 관심을 끌고 있다. 한편,
- 김갑성 기자
- 2025-12-22 14:12
The 8th Hainan International Health Industry Expo opens in Sanya

HAIKOU, China, Dec. 22, 2025 -- A report from Hainan International Media Center: On December 20, 2025, the 8th Hainan International Health Industry Expo opened in Sanya. Coinciding with the crucial juncture of the Hainan Free Trade Port's island-wide special customs operations, this Expo serves as both a platform for Hainan to showcase achievements in the development of the health industry and as a window to envision the future of the health industry. This year's 4-day 12,000m² Expo has attracted 253 domestic and international companies to participate and covers innovative
- 김갑성 기자
- 2025-12-22 11:44
Manulife Hong Kong Partners with Hong Kong Baptist Hospital to Launch Outpatient Cashless Service for Cancer Day Treatment

HONG KONG, Dec. 22, 2025 -- Manulife Hong Kong today announced an expansion of its partnership with Hong Kong Baptist Hospital (HKBH) through the launch of an outpatient cashless service[1] for cancer day treatment at both HKBH and its East Kowloon Medical Centre (EKMC). This initiative aims to provide greater financial convenience during treatment, while reinforcing Manulife's commitment to providing holistic health solutions and enhancing access to quality care for its customers. In response to growing demand for accessible treatment options, the outpatient cashless service enables e
- 황정호 기자
- 2025-12-22 11:00
Wong To Yick Unveils Revitalised Official Website

Launching a New No.1 Brand Chapter with Ambassador Joey Yung Enhanced Authenticity Guidance & Usage Education for Elevated Consumer Confidence [High-resolution promotional photo download: Here] HONG KONG, Dec. 22, 2025 -- Wong To Yick, the iconic Hong Kong medicated balm brand trusted for over half a century, proudly unveils its newly upgraded official website, marking a significant milestone in the brand's global expansion journey. As the second major initiative under its brand upgrading programme, the new digital platform follows the earlier announcement
- 김갑성 기자
- 2025-12-22 09:00
Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award"

HONG KONG, Dec. 22, 2025 -- On 19 December 2025, the TVB ESG Awards 2025 Presentation Ceremony, hosted by Television Broadcasts Limited ("TVB"), was held at the Hong Kong Convention and Exhibition Center. Fosun International was honored with the highest accolade, the "Outstanding ESG Award", as well as awards for "Best in ESG Practices" and "Best in ESG Report". Mr. Wong Wai Lun, Michael, GBS, JP, Deputy Financial Secretary of the Government of the Hong Kong Special Administrative Region (SAR), Mr. Siu Sai Wo, General Manager (Business Operations
- 김갑성 기자
- 2025-12-22 09:00
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China. TLX101-CDx (Pixclara®[1], 18F-floretyrosine), PET imaging candidate for glioma: Following collaborative interactions with the FDA, finalizing NDA resubmission and expect to provide a f
- 김갑성 기자
- 2025-12-22 05:40
T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

BEIJING, Dec. 21, 2025 -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblastoma (rGBM). This milestone marks a significant breakthrough in addressing one of the most formidable challenges in oncology: developing effective allogeneic CAR-T therapies for solid tumors. "The FDA's clearance of the IND for MT027 represents a strong validation of our strategic commitment to tacklin
- 김갑성 기자
- 2025-12-21 20:20
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China. Under the terms of the agreement, Jacobio will receive an upfront payment of US$100 million, and is eligible for additional development and commercial milestone payments of up to US$1.915 billion, as well as tiered royal
- 김갑성 기자
- 2025-12-21 20:15
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC

SUZHOU, China, Dec. 20, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been granted breakthrough therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube c
- 김갑성 기자
- 2025-12-20 12:54
Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards

SINGAPORE, Dec. 20, 2025 -- Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company's exhibition booth. 2025 has marked a year of substantial progress for Gene Solutions, with expanded presence and partnerships across India, Turkey, Taiwan
- 김갑성 기자
- 2025-12-20 11:14

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 16시 00분